PubMed Health⌕ Search

PubMed · 3992233

[Sudden cardiac death].

Abstract

Sudden cardiac death, most often due to ventricular fibrillation, is caused by three vessel coronary disease in over 90% of the cases. At autopsy acute coronary thrombosis superimposed on an arteriosclerotic plaque is often found. However, a terminal myocardial ischemia can also develop without coronary thrombosis. In these cases platelet thrombi or coronary spasm may be the cause of ventricular fibrillation. In approximately one fourth of all patients with coronary disease sudden death is the first manifestation of the patient's illness. After myocardial infarction a high risk patient group can be detected by non-invasive methods: patients with cardiac failure, high enzyme values, a positive exercise-ECG and malignant ventricular arrhythmias three weeks after myocardial infarction have a significantly higher mortality in the following 12 months than patients without these complications. In this group of patients prevention of sudden death should be tried by an aggressive management of myocardial ischemia, heart failure and ventricular arrhythmias.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Denier, H R Baur. 1985-04-13. [Sudden cardiac death].. https://pubmed.ncbi.nlm.nih.gov/3992233/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗